Skip to content
My WebMD Sign In, Sign Up

Migraines & Headaches Health Center

Font Size

New Drugs May Help Prevent Migraines

Two early trials show two experimental compounds reduced number of headaches for sufferers

WebMD News from HealthDay

By Amy Norton

HealthDay Reporter

TUESDAY, April 22, 2014 (HealthDay News) -- Two experimental drugs may help prevent migraines in people who suffer multiple attacks a month, according to preliminary findings from a pair of clinical trials.

The drugs, one given by IV and one by injection, are part of a new approach to preventing migraine headaches. They are "monoclonal antibodies" that target a tiny protein called the calcitonin gene-related peptide (CGRP) -- which recent research has implicated in triggering migraine pain.

In one study, patients saw a 66 percent reduction in their migraine attacks five to eight weeks after a single dose of the IV drug -- known for now as ALD403. That compared with a 52 percent decrease among patients who were given a placebo, or inactive, infusion.

In the other trial, patients receiving the injection drug saw a similar benefit from three months' worth of biweekly treatments.

The findings, scheduled to be presented Tuesday at the American Academy of Neurology's annual meeting in Philadelphia, are preliminary. And experts stressed that many questions remain.

Still, migraine sufferers can "take heart" that new drugs, specific to the pain condition, are under development, said Dr. Peter Goadsby, a neurologist at the University of California, San Francisco, who worked on both studies.

Right now, he said, the drugs used to prevent migraines are all older medications that were originally developed to treat other conditions. They include certain antidepressants, high blood pressure medications and anti-seizure drugs.

In contrast, the experimental medications aimed at CGRP are the first "designer drugs" for preventing migraine, said Dr. Richard Lipton, a headache expert who was not involved in the studies.

These early findings are "very encouraging," said Lipton, who directs the Montefiore Headache Center in New York City. "To me, this proves the concept that targeting CGRP can be effective," he said.

However, larger, longer-term studies are still needed to confirm the drugs' effectiveness and safety, Lipton and Goadsby said.

The trial testing ALD403, the IV drug, included 163 patients who were randomly assigned to receive either a single dose of the drug or a placebo infusion. Before treatment, all of the patients were suffering migraines five to 14 days out of every month.

Five to eight weeks later, patients given the drug were having 5.6 fewer "migraine days" per month on average -- a 66 percent drop. The placebo group also saw an improvement, of 4.6 fewer migraine days. Still, the benefit of the drug was significant in statistical terms, Lipton pointed out.

In the other trial, 217 patients received either the injection drug -- by the name of LY2951742 -- or a placebo, biweekly for 12 weeks.

Again, both groups got some migraine relief, but the benefit was bigger for patients on the real drug. They had 4.2 fewer migraine days a month, or a 63 percent decline. The placebo patients had three fewer migraine days, or a 42 percent decrease.

Today on WebMD

woman receiving acupuncture
14 alternative methods for migraine relief.
woman with migraine
Get the truth about migraines.
 
headache in the bedroom
Keep headaches from ruining your sex life.
desert heat
12 surprising headache triggers.
 
woman with migraine
Quiz
drinking coffee
Article
 
Migraines Headaches Basics
Article
acupuncture needles in woman's back
Slideshow
 
young woman with migraine
Articles
spraying perfume
Article
 
man with a headache
Article
headache in the bedroom
Article
 

Special Sections